Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Journal of Affective Disorders|November 27, 2010
Screening for bipolar disorder in patients consulting general practitioners in FranceFrédéric Rouillon, Isabelle Gasquet, Ricardo P Garay, et al.
European Journal of Pharmacology|November 1, 2006
Role of chloride transport proteins in the vasorelaxant action of nitroprusside in isolated rat aortaMarta Valero, Désirée Pereboom, Ricardo P Garay, et al.
Expert Opinion on Investigational Drugs|November 26, 2014
Investigational drugs for anxiety in patients with schizophreniaRicardo P Garay, Ludovic Samalin, Ahcène Hameg, et al.
European Journal of Pharmacology|July 25, 2006
Cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel and Na-K-Cl cotransporter NKCC1 isoform mediate the vasorelaxant action of genistein in isolated rat aortaMarta S Valero, Ricardo P Garay, Pilar Gros, et al.
European Journal of Pharmacology|March 3, 2005
Inhibition of choroidal angiogenesis by calcium dobesilate in normal Wistar and diabetic GK ratsStéphane Lameynardie, Carlo Chiavaroli, Pierre Travo, et al.
European Journal of Pharmacology|April 8, 2003
Vascular permeabilization by intravenous arachidonate in the rat peritoneal cavity: antagonism by ethamsylatePatrick Hannaert, Miriam Alvarez-Guerra, Hamida Hider, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|October 26, 2005
Double-blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndromePatrick Lemoine, Imane Kermadi, Stéphanie Garcia-Acosta, et al.
European Journal of Pharmacology|November 8, 2002
5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscleMiriam Alvarez-Guerra, Ahcène Hameg, Franck Bayle, et al.
European Journal of Pharmacology|April 8, 2003
Vascular permeabilization by intravenous arachidonate in the rat peritoneal cavity: antagonism by antioxidantsMiriam Alvarez-Guerra, Patrick Hannaert, Hamida Hider, et al.
Expert Review of Neurotherapeutics|August 1, 2022
Fifty years of experience with loxapine for the rapid non-coercive tranquilization of acute behavioral disturbances in schizophrenia patients, and beyondPhilippe Nuss, Emmanuelle Corruble, Emmanuelle Baloche, et al.
Pageof 5